Bokf Na Sells 148 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Bokf Na decreased its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 0.7% during the 1st quarter, Holdings Channel reports. The firm owned 22,518 shares of the medical research company’s stock after selling 148 shares during the quarter. Bokf Na’s holdings in Laboratory Co. of America were worth $4,872,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp grew its stake in Laboratory Co. of America by 3.0% in the fourth quarter. Northern Trust Corp now owns 1,163,252 shares of the medical research company’s stock valued at $264,396,000 after acquiring an additional 33,493 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Laboratory Co. of America by 17.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 101,019 shares of the medical research company’s stock valued at $22,069,000 after acquiring an additional 14,708 shares during the period. Bank of Nova Scotia grew its stake in Laboratory Co. of America by 1,715.7% in the fourth quarter. Bank of Nova Scotia now owns 175,176 shares of the medical research company’s stock valued at $39,814,000 after acquiring an additional 165,528 shares during the period. SG Americas Securities LLC grew its stake in Laboratory Co. of America by 283.1% in the first quarter. SG Americas Securities LLC now owns 23,217 shares of the medical research company’s stock valued at $5,072,000 after acquiring an additional 17,156 shares during the period. Finally, First National Bank of Mount Dora Trust Investment Services acquired a new stake in Laboratory Co. of America in the first quarter valued at approximately $1,418,000. Institutional investors own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on LH shares. Truist Financial cut their target price on Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. JPMorgan Chase & Co. cut their target price on Laboratory Co. of America from $261.00 to $243.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. Barclays cut their target price on Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Evercore ISI lifted their target price on Laboratory Co. of America from $210.00 to $215.00 and gave the company an “in-line” rating in a research report on Tuesday, July 9th. Finally, StockNews.com cut Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Tuesday, June 4th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.29.

Insider Buying and Selling at Laboratory Co. of America

In other Laboratory Co. of America news, CAO Peter J. Wilkinson sold 2,439 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $204.33, for a total value of $498,360.87. Following the sale, the chief accounting officer now directly owns 2,087 shares in the company, valued at $426,436.71. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Der Vaart Sandra D. Van sold 2,000 shares of Laboratory Co. of America stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $210.83, for a total value of $421,660.00. Following the completion of the transaction, the executive vice president now directly owns 5,637 shares in the company, valued at $1,188,448.71. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Peter J. Wilkinson sold 2,439 shares of Laboratory Co. of America stock in a transaction on Monday, April 29th. The shares were sold at an average price of $204.33, for a total value of $498,360.87. Following the completion of the transaction, the chief accounting officer now owns 2,087 shares of the company’s stock, valued at $426,436.71. The disclosure for this sale can be found here. Insiders have sold a total of 4,939 shares of company stock worth $1,021,078 over the last ninety days. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Stock Performance

Shares of LH traded up $1.18 during mid-day trading on Friday, hitting $210.90. The stock had a trading volume of 395,638 shares, compared to its average volume of 495,470. The firm has a market cap of $17.78 billion, a P/E ratio of 42.43, a PEG ratio of 1.59 and a beta of 1.05. The business has a fifty day moving average price of $203.26 and a 200-day moving average price of $210.52. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.88 and a quick ratio of 0.76. Laboratory Co. of America Holdings has a 52 week low of $191.97 and a 52 week high of $234.09.

Laboratory Co. of America (NYSE:LH) last issued its earnings results on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.20. The firm had revenue of $3.18 billion for the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a return on equity of 14.68% and a net margin of 3.52%. The business’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.82 earnings per share. On average, equities research analysts expect that Laboratory Co. of America Holdings will post 14.84 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Thursday, August 29th will be paid a $0.72 dividend. The ex-dividend date is Thursday, August 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.37%. Laboratory Co. of America’s payout ratio is presently 57.95%.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).